Name:
Genetics in DC A Report from ASHG - DAY1
Description:
Genetics in DC A Report from ASHG - DAY1
Thumbnail URL:
https://cadmoremediastorage.blob.core.windows.net/79386113-c308-4038-a8f8-ecfdf564c745/videoscrubberimages/Scrubber_1.jpg?sv=2019-02-02&sr=c&sig=19TZCFOx9%2FRDtyfJx1VPYIigHGOsnuJJxTSQgQK6zd4%3D&st=2024-12-22T05%3A53%3A19Z&se=2024-12-22T09%3A58%3A19Z&sp=r
Duration:
T00H09M05S
Embed URL:
https://stream.cadmore.media/player/79386113-c308-4038-a8f8-ecfdf564c745
Content URL:
https://cadmoreoriginalmedia.blob.core.windows.net/79386113-c308-4038-a8f8-ecfdf564c745/Genetics in DC A Report from ASHG-DAY1.mp4?sv=2019-02-02&sr=c&sig=Af7mYgdc2Dou6gI%2BGL%2BXEi5H8lDER91zHlaltE7qsZQ%3D&st=2024-12-22T05%3A53%3A19Z&se=2024-12-22T07%3A58%3A19Z&sp=r
Upload Date:
2023-11-06T00:00:00.0000000
Transcript:
Language: EN.
Segment:0 .
[MUSIC PLAYING]
KEVIN DAVIES: Hello, everybody. Kevin Davies and Julianna LeMieux from GEN here at ASHG in Washington, DC, the 75th anniversary of the society. And boy, it's good to be back at a live convention again. Hi, Julianna. How's day one treated you so far?
JULIANNA LEMIEUX: Hi, Kevin. Good to see you. Day one has been great and full. I just took the train down from New York City this morning. And it's just been a very packed day, lots going on, as always.
KEVIN DAVIES: As always. So, I mean, you spent the last year writing a lot about NGS and spatial. Are those two of the big themes? Or have you been hearing about anything else that's caught your attention?
JULIANNA LEMIEUX: Yeah. You know, of course, all the NGS companies are here, and they are here in full force with, you know, lots of talks and workshops and lunch workshops and also big expo booths downstairs. So you can't miss the NGS companies. And they all, you know, they all seem to be going really strong, lots of enthusiasm and momentum, so that's been really fun. But I will say, before we get into NGS too much, another thing that I have seen, Kevin-- and again, I've only been here one day.
JULIANNA LEMIEUX: Well, it just started last night, but I've only been here one day. But I've seen a real presence of proteomics companies this year. So whether it's kind of the more large-scale proteomics companies, like SomaLogic and Olink, or the protein sequencing companies, there's just a lot more focus on proteomics. And I wonder if someday they're going to have to call this ASHG&P because there's so many proteomics going on, but we'll see.
KEVIN DAVIES: OK. I hadn't thought about it in those terms. But yes, SomaLogic and Olink, of course, both recently merged or acquired by Standard Tool and Thermo respectively, so a lot going on in that space.
JULIANNA LEMIEUX: Yeah. And I met with SomaLogic this morning and wrote a story. So actually, they've had a significant increase in the number of proteins that their assay can detect. And I wrote up that story, actually, for our ASHG newsletter, Kevin. So we have a newsletter going out every day--
KEVIN DAVIES: You do?
JULIANNA LEMIEUX: --tomorrow, the next day. Eight stories in each newsletter, so lots of news coming out of ASHG, so we're busy talking to people, and we're busy writing and doing all the things.
KEVIN DAVIES: Yeah. It feels like the whole office has come down from New York, almost, to cover this. Colleagues from our sister magazine Inside Precision Medicine are here as well. I covered the president's address yesterday, Brendan Lee, a very distinguished physician scientist at Baylor College of Medicine working on a variety of skeletal disorders. Very nice look at the past, present, and future of the society, reviewing some of the big milestones.
KEVIN DAVIES: And of course, it's been an amazing ride in genomics and genetics over the last two or three decades and lots to look forward to in precision medicine. So I thought that was a very nice, nice talk. And I liked the way that he began with his disclosure slide saying there was absolutely no use of AI in the preparation of any of these, any of these slides, which I suspect is a disclaimer that we're going to be hearing more and more of as these conferences go on.
JULIANNA LEMIEUX: Yeah.
KEVIN DAVIES: So what else? You have NGS-- aside from proteomics, you've been talking to a lot of NGS companies, I'm sure, over the course of the day.
JULIANNA LEMIEUX: Yeah. So I had a great meeting with Gordon Sanghera and a nice conversation about where ONT is right now. And I mean, he's really excited about moving into the application space.
KEVIN DAVIES: The CEO of Oxford Nanopore?
JULIANNA LEMIEUX: Oh, sorry. Yeah, I should have said CEO of Oxford Nanopore. Also, of course, caught up with PacBio before the conference and got to chat with Christian Henry a bit about what he's looking forward to. Also, actually, he mentioned talking about diagnostics and moving into multiomics. So interesting that those two longer-read NGS companies are both looking towards more clinical applications and looking beyond just kind of research sequencing.
JULIANNA LEMIEUX: But of course, speaking of PacBio, all anyone is talking about is the PacBio party tonight and the best-kept secret at ASHG, which is who is going to be the performer. So of course, you know, Kevin, that last year at ASHG, it was Maroon 5. Then at AGBT they had Flo Rida give a performance. So who is it going to be tonight? All we know is that it's a Grammy Award winner.
JULIANNA LEMIEUX: And I asked Christian when I interviewed him before the conference if he would reveal it in my article. I thought that would be the best place to do it.
KEVIN DAVIES: Best scoop ever, yeah.
JULIANNA LEMIEUX: And he said, I can tell you two things. One is it's not going to be maroon five. And two, it's going to be very cool.
KEVIN DAVIES: Very cool? Oh, so interesting because remember, last year, I remember when you interviewed him, he said his first choice was Coldplay.
JULIANNA LEMIEUX: Yes. And that's why, Kevin, I think tonight-- so he told me his first choice was Coldplay, but they couldn't get Coldplay. But I think maybe, like, year two, maybe they got it. Maybe it's Coldplay.
KEVIN DAVIES: No. That would be incredible. I hear The Rolling Stones are back together, so maybe, you know. Well, all will be revealed. I'm sure somebody from GEN will be tweeting out the moment we see the dry ice clear and whoever it is step on stage. It has been a pretty well and closely guarded secret. So before this completely deteriorates, any other news? I mean, Element is here, Singular here.
KEVIN DAVIES: I haven't seen Ultima who you just wrote a big story about.
JULIANNA LEMIEUX: [INAUDIBLE] Ultima is here. Yes, Ultima is here, Element and Singular. As I said, I talked to ONT, PacBio. Of course, illumina is here. And I will say, I also met with Complete today as well. And their message is, you know, we're here. We're selling our sequencers. We have a fleet of instruments. They also mentioned that they are the only sequencing company that sells the robotics together with the sequencers.
JULIANNA LEMIEUX: So you know, you can use your sequencers and then also, you know, go by your robotics somewhere else. But they actually have them all the same, which is good for, like, sharing information and things like that. So I think is that-- did we just mention everybody? I think we did. They are all--
KEVIN DAVIES: I think we sort of did. Yeah. I mean, I had a nice-- I also stopped by Complete. I had a nice catch up with Radoje Drmanac who I've followed for many years and great to see him. And then they invited Mike Snyder, of course, the very well-known Stanford geneticist to give one of those short little talks on the exhibit hall floor.
KEVIN DAVIES: And he was singing Complete's praises. Although he was singing a lot of companies' praises. It wasn't as if it was the a huge infomercial but talking about a new phased genome sequencing toolkit, I guess you could say, which he applied, not surprisingly, to his own genome because he's probably the most sequenced person on the planet, I suspect. And he was quite impressed. He said, you know, the name of the company is Complete Genomics.
KEVIN DAVIES: And in the last three weeks from when he gave his blood sample, they've produced a pretty complete phase genome. He was really, I think, very bullish on the quality and the price of this which would be in the few hundreds of dollars, so good to see Complete really making strides. I'm happy for them. Well, it's been great seeing you here in DC, Julianna. And I'm sure I'll, I guess, run into you on the dance floor a little bit later on this evening as we both manage to snag very hard-to-find PacBio tickets.
KEVIN DAVIES: So it's good that somebody is doing this. This used to be a luminous play, right? The big party that you had to get in to be cool or not. And it seems that PacBio has sort of inherited that mantle, so to speak.
JULIANNA LEMIEUX: Once, I tweeted that PacBio has, on their own, really changed the-- when I say I'm going on a work trip to my family, and then I come home with these videos of me at big concerts, it's like they've really changed the definition of work trip, I think. So thank you for that. We'll take it.
KEVIN DAVIES: All right. Well, if we're recovered tomorrow, we'll do another one of these video recaps.
JULIANNA LEMIEUX: [INAUDIBLE]
KEVIN DAVIES: Thanks, everyone, for watching. And stay tuned. We'll have more for you coming up. So I'm Kevin, she's Julianna. Thanks for watching.
JULIANNA LEMIEUX: Bye, Kevin. [MUSIC PLAYING]
Form Title Download
Form Title Bookmark
Form Title Share
Form Title Cite
